Post Profile

Merck's Keytruda achieves 24 percent response in bladder cancer study

(Reuters) - Merck & Co's immunotherapy Keytruda proved effective as an initial treatment for nearly a quarter of patients with advanced bladder cancer too frail for standard cisplatin chemotherapy, according to interim results from a study presented on Saturday.
read more


Related Posts

Merck Cancer Drug Shines Against Skin, Lung Cancer

Business & Finance : Forbes: Business

Merck’s immune-boosting cancer drug, Keytruda, bested the standard of care in advanced melanoma, the deadly skin cancer, and showed promising results in non-small cell lung cancer. Based on these data, Merck says it will file an app...

Merck Serono Initiates TH-302 Phase III MAESTRO Study In Patients With Locally Advanced Or Metastatic Pancreatic Adenocarcinoma

Health : Medical News Today

Pivotal Phase III study with investigational hypoxia-targeted drug aims to enroll 660 patients Merck Serono, a division of Merck, Darmstadt, Germany, have announced the initiation of the global Phase III MAESTRO study, assessing the...

Additional interim data for MK-3475 shows estimated overall survival rate of 81 percent at one year in patients with advanced melanoma

Health : Medical News Today

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma that showed an estimated overall surviv...

Merck KGaA Starts Stimuvax Phase III Study INSPIRE In Asian Patients With Advanced NSCLC

Health : Medical News Today

Merck KGaA announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The I...

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...


Copyright © 2016 Regator, LLC